You have been in this stock for 3 years and could not book profit when it was trading over $22?? And you are posting 10 times day on this board and want this desperately to go back to $20s? Is that smart investment?
You can take that as a huge potential or take that as having hard time penetrating doctor mkt. Miracle medicines will reach the doctor without sales people. Also I heard theie sales force have a very hard time getting into hospitals and reaching doctors.
Do you know why then it was trading near 52 week low at $9.50 yesterday just before this pop? There has to be a reason for that. Market is not that irrational.
It could not sustain the pop yesterday. Pooped with few 1000 shares to 12 and then straight to 14 with gap after the trade halt lift. Any one went long between 12.50 and 14 are under water already with 10% loss. If there were people buying, then people were either shorting or selling too to pull this down back to 12 from 14. Probably these were all day traders who lost big on the market yesterday hoping to make money on anything, which probably didn't work here either. As I said if everything works, this could go up big.
The short interest on this company not that high. Around 8%. Which is relatively small for a biotec.
I know your answer. Oh I am not a short term trader, I am here for a long term. But you seem to be posting here every 30 minutes, tells me you are a short term trader.
A similar patent settlement in Oct 2015 with Endo Pharma ENDP for Trokendi XRm which accounts for over 75% of rev and growth didn't move this stock much. Well it popped and then dropped. This new patent protection win for Oxtellar XR is similar and no different. Oxtellar XR accounts for less than 25% of Rev and less growth potential. I don't understand the valuation of this stock, but a 40% pop or any pop on a similar case seems over done.
And these patent cases tells you that Trokendi and Oxtellar XR may not be that innovative and border line generic already -- even though the patents are protected for just 11 more years. Probably one of the main reason market doesn't want to give this stock a much higher valuation. There are two drugs on the pipeline, but needs to go through pahse 3s. Seeking alphas and people are drumming over 1 Bil sales for the new drugs, but give a break. Until phase 3 completes and come to market no one knows. There are other competitive drug trials already underway in phase 3 for ADHD, so they are behind the play.
If they miss sales in the ER, this could go below $8. Until the pase 3 of the new drugs, there is nothing exciting for another 2 years.